How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?
To evaluate the clinical impact of Ga-prostate-specific membrane antigen positron emission tomography/computed tomography on the planned management of prostate cancer patients with biochemical recurrence after surgery. We enrolled 276 prostate cancer patients referred to Ga-prostate-specific membran...
Gespeichert in:
| Veröffentlicht in: | International journal of urology 2019-08, Vol.26 (8), p.804-811 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 811 |
|---|---|
| container_issue | 8 |
| container_start_page | 804 |
| container_title | International journal of urology |
| container_volume | 26 |
| creator | Bianchi, Lorenzo Schiavina, Riccardo Borghesi, Marco Ceci, Francesco Angiolini, Andrea Chessa, Francesco Droghetti, Matteo Bertaccini, Alessandro Manferrari, Fabio Marcelli, Emanuela Cochetti, Giovanni Porreca, Angelo Castellucci, Paolo Fanti, Stefano Brunocilla, Eugenio |
| description | To evaluate the clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography on the planned management of prostate cancer patients with biochemical recurrence after surgery.
We enrolled 276 prostate cancer patients referred to
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography due to biochemical recurrence after surgery (two consecutive prostate-specific antigen assays ≥0.2 ng/mL). First, the detection rate of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed according to different prostate-specific antigen levels. Second, the independent predictors of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography positive results were assessed. Finally, the intended treatment before revision of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed by a multidisciplinary team based on the European Association of Urology guidelines, patient clinical condition and clinical parameters. Then, re-assessment of the treatment plan was prospectively recorded by the same board after revision of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography. The effective clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was rated as major (change in therapeutic approach), minor (same treatment, but modified therapeutic strategy) or none.
The overall detection rate of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 47.5%. Prostate-specific antigen at
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (odds ratio 3.52) and prostate-specific antigen doubling time |
| doi_str_mv | 10.1111/iju.14012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2231994344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2231994344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1304-fc73a9e1b46a2be4f60130df5a1d72c1ba49b19daed1b6776f1b6346ccd461963</originalsourceid><addsrcrecordid>eNpNUctOHDEQtKKgsDwO_EDkYzgMuG0zjxNCiEAkpFzgPOrxtHeN1uOJ7RHa7-IHY8JD6UuXSqXuri7GTkCcQalz97ScgRYgv7AVaC0rKbT8ylaig65qoZH77CClJyFASWi_sX0FolVNq1fs5S488zFQ4nXLb7GaY0gZM1VpJuOsM9yTHyJOxHHKbk0Tn0NyOYaJk3cpuQJy8GEdcd7szk3w85Jp_I_jzs9oMs8b4h4nXJOnKfNg-YzZFZj4s8sb_rGaG5wMRR7JLDFSwRxtLkRa4pri7vKI7VncJjp-74fs8efNw_Vddf_79tf11X1lQAldWdMo7AgGXaMcSNu6-BejvUAYG2lgQN0N0I1IIwx109S2NKVrY0ZdQ1erQ_bjbW657M9CKffFsKHttnwjLKmXUkHXaaV1kZ6-SU0xkSLZfo7OY9z1IPrXjPqSUf8vo6L9_j52GTyNn8qPUNRfv02R9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2231994344</pqid></control><display><type>article</type><title>How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Bianchi, Lorenzo ; Schiavina, Riccardo ; Borghesi, Marco ; Ceci, Francesco ; Angiolini, Andrea ; Chessa, Francesco ; Droghetti, Matteo ; Bertaccini, Alessandro ; Manferrari, Fabio ; Marcelli, Emanuela ; Cochetti, Giovanni ; Porreca, Angelo ; Castellucci, Paolo ; Fanti, Stefano ; Brunocilla, Eugenio</creator><creatorcontrib>Bianchi, Lorenzo ; Schiavina, Riccardo ; Borghesi, Marco ; Ceci, Francesco ; Angiolini, Andrea ; Chessa, Francesco ; Droghetti, Matteo ; Bertaccini, Alessandro ; Manferrari, Fabio ; Marcelli, Emanuela ; Cochetti, Giovanni ; Porreca, Angelo ; Castellucci, Paolo ; Fanti, Stefano ; Brunocilla, Eugenio</creatorcontrib><description>To evaluate the clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography on the planned management of prostate cancer patients with biochemical recurrence after surgery.
We enrolled 276 prostate cancer patients referred to
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography due to biochemical recurrence after surgery (two consecutive prostate-specific antigen assays ≥0.2 ng/mL). First, the detection rate of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed according to different prostate-specific antigen levels. Second, the independent predictors of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography positive results were assessed. Finally, the intended treatment before revision of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed by a multidisciplinary team based on the European Association of Urology guidelines, patient clinical condition and clinical parameters. Then, re-assessment of the treatment plan was prospectively recorded by the same board after revision of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography. The effective clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was rated as major (change in therapeutic approach), minor (same treatment, but modified therapeutic strategy) or none.
The overall detection rate of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 47.5%. Prostate-specific antigen at
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (odds ratio 3.52) and prostate-specific antigen doubling time <3 months (odds ratio 3.98) were independent predictors of positive
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography results (all P ≤ 0.03).
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography led to a major treatment change in 177 cases (64.1%), with a minor clinical impact of 2.5%. The overall clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 42.4%, 27.7%, 21.2% and 8.7% in men with prostate-specific antigen at
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography of 0.2-0.4, 0.5-1, 1.1-2 and >2 ng/mL, respectively.
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography allows clinicians to radically change the intended treatment approach before imaging evaluation, in roughly two out three individuals.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/iju.14012</identifier><identifier>PMID: 31083784</identifier><language>eng</language><publisher>Australia</publisher><subject>Aged ; Androgen Antagonists - therapeutic use ; Chemoradiotherapy, Adjuvant - methods ; Clinical Decision-Making - methods ; Feasibility Studies ; Humans ; Kallikreins - blood ; Male ; Membrane Glycoproteins - administration & dosage ; Middle Aged ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnosis ; Organometallic Compounds - administration & dosage ; Patient Selection ; Positron Emission Tomography Computed Tomography - methods ; Prospective Studies ; Prostate - diagnostic imaging ; Prostate - surgery ; Prostate-Specific Antigen - blood ; Prostatectomy ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - therapy ; Radiopharmaceuticals - administration & dosage</subject><ispartof>International journal of urology, 2019-08, Vol.26 (8), p.804-811</ispartof><rights>2019 The Japanese Urological Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1304-fc73a9e1b46a2be4f60130df5a1d72c1ba49b19daed1b6776f1b6346ccd461963</citedby><cites>FETCH-LOGICAL-c1304-fc73a9e1b46a2be4f60130df5a1d72c1ba49b19daed1b6776f1b6346ccd461963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31083784$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bianchi, Lorenzo</creatorcontrib><creatorcontrib>Schiavina, Riccardo</creatorcontrib><creatorcontrib>Borghesi, Marco</creatorcontrib><creatorcontrib>Ceci, Francesco</creatorcontrib><creatorcontrib>Angiolini, Andrea</creatorcontrib><creatorcontrib>Chessa, Francesco</creatorcontrib><creatorcontrib>Droghetti, Matteo</creatorcontrib><creatorcontrib>Bertaccini, Alessandro</creatorcontrib><creatorcontrib>Manferrari, Fabio</creatorcontrib><creatorcontrib>Marcelli, Emanuela</creatorcontrib><creatorcontrib>Cochetti, Giovanni</creatorcontrib><creatorcontrib>Porreca, Angelo</creatorcontrib><creatorcontrib>Castellucci, Paolo</creatorcontrib><creatorcontrib>Fanti, Stefano</creatorcontrib><creatorcontrib>Brunocilla, Eugenio</creatorcontrib><title>How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>To evaluate the clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography on the planned management of prostate cancer patients with biochemical recurrence after surgery.
We enrolled 276 prostate cancer patients referred to
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography due to biochemical recurrence after surgery (two consecutive prostate-specific antigen assays ≥0.2 ng/mL). First, the detection rate of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed according to different prostate-specific antigen levels. Second, the independent predictors of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography positive results were assessed. Finally, the intended treatment before revision of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed by a multidisciplinary team based on the European Association of Urology guidelines, patient clinical condition and clinical parameters. Then, re-assessment of the treatment plan was prospectively recorded by the same board after revision of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography. The effective clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was rated as major (change in therapeutic approach), minor (same treatment, but modified therapeutic strategy) or none.
The overall detection rate of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 47.5%. Prostate-specific antigen at
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (odds ratio 3.52) and prostate-specific antigen doubling time <3 months (odds ratio 3.98) were independent predictors of positive
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography results (all P ≤ 0.03).
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography led to a major treatment change in 177 cases (64.1%), with a minor clinical impact of 2.5%. The overall clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 42.4%, 27.7%, 21.2% and 8.7% in men with prostate-specific antigen at
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography of 0.2-0.4, 0.5-1, 1.1-2 and >2 ng/mL, respectively.
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography allows clinicians to radically change the intended treatment approach before imaging evaluation, in roughly two out three individuals.</description><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Chemoradiotherapy, Adjuvant - methods</subject><subject>Clinical Decision-Making - methods</subject><subject>Feasibility Studies</subject><subject>Humans</subject><subject>Kallikreins - blood</subject><subject>Male</subject><subject>Membrane Glycoproteins - administration & dosage</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Organometallic Compounds - administration & dosage</subject><subject>Patient Selection</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Prospective Studies</subject><subject>Prostate - diagnostic imaging</subject><subject>Prostate - surgery</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Radiopharmaceuticals - administration & dosage</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNUctOHDEQtKKgsDwO_EDkYzgMuG0zjxNCiEAkpFzgPOrxtHeN1uOJ7RHa7-IHY8JD6UuXSqXuri7GTkCcQalz97ScgRYgv7AVaC0rKbT8ylaig65qoZH77CClJyFASWi_sX0FolVNq1fs5S488zFQ4nXLb7GaY0gZM1VpJuOsM9yTHyJOxHHKbk0Tn0NyOYaJk3cpuQJy8GEdcd7szk3w85Jp_I_jzs9oMs8b4h4nXJOnKfNg-YzZFZj4s8sb_rGaG5wMRR7JLDFSwRxtLkRa4pri7vKI7VncJjp-74fs8efNw_Vddf_79tf11X1lQAldWdMo7AgGXaMcSNu6-BejvUAYG2lgQN0N0I1IIwx109S2NKVrY0ZdQ1erQ_bjbW657M9CKffFsKHttnwjLKmXUkHXaaV1kZ6-SU0xkSLZfo7OY9z1IPrXjPqSUf8vo6L9_j52GTyNn8qPUNRfv02R9Q</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Bianchi, Lorenzo</creator><creator>Schiavina, Riccardo</creator><creator>Borghesi, Marco</creator><creator>Ceci, Francesco</creator><creator>Angiolini, Andrea</creator><creator>Chessa, Francesco</creator><creator>Droghetti, Matteo</creator><creator>Bertaccini, Alessandro</creator><creator>Manferrari, Fabio</creator><creator>Marcelli, Emanuela</creator><creator>Cochetti, Giovanni</creator><creator>Porreca, Angelo</creator><creator>Castellucci, Paolo</creator><creator>Fanti, Stefano</creator><creator>Brunocilla, Eugenio</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201908</creationdate><title>How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?</title><author>Bianchi, Lorenzo ; Schiavina, Riccardo ; Borghesi, Marco ; Ceci, Francesco ; Angiolini, Andrea ; Chessa, Francesco ; Droghetti, Matteo ; Bertaccini, Alessandro ; Manferrari, Fabio ; Marcelli, Emanuela ; Cochetti, Giovanni ; Porreca, Angelo ; Castellucci, Paolo ; Fanti, Stefano ; Brunocilla, Eugenio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1304-fc73a9e1b46a2be4f60130df5a1d72c1ba49b19daed1b6776f1b6346ccd461963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Chemoradiotherapy, Adjuvant - methods</topic><topic>Clinical Decision-Making - methods</topic><topic>Feasibility Studies</topic><topic>Humans</topic><topic>Kallikreins - blood</topic><topic>Male</topic><topic>Membrane Glycoproteins - administration & dosage</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Organometallic Compounds - administration & dosage</topic><topic>Patient Selection</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Prospective Studies</topic><topic>Prostate - diagnostic imaging</topic><topic>Prostate - surgery</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Radiopharmaceuticals - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bianchi, Lorenzo</creatorcontrib><creatorcontrib>Schiavina, Riccardo</creatorcontrib><creatorcontrib>Borghesi, Marco</creatorcontrib><creatorcontrib>Ceci, Francesco</creatorcontrib><creatorcontrib>Angiolini, Andrea</creatorcontrib><creatorcontrib>Chessa, Francesco</creatorcontrib><creatorcontrib>Droghetti, Matteo</creatorcontrib><creatorcontrib>Bertaccini, Alessandro</creatorcontrib><creatorcontrib>Manferrari, Fabio</creatorcontrib><creatorcontrib>Marcelli, Emanuela</creatorcontrib><creatorcontrib>Cochetti, Giovanni</creatorcontrib><creatorcontrib>Porreca, Angelo</creatorcontrib><creatorcontrib>Castellucci, Paolo</creatorcontrib><creatorcontrib>Fanti, Stefano</creatorcontrib><creatorcontrib>Brunocilla, Eugenio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bianchi, Lorenzo</au><au>Schiavina, Riccardo</au><au>Borghesi, Marco</au><au>Ceci, Francesco</au><au>Angiolini, Andrea</au><au>Chessa, Francesco</au><au>Droghetti, Matteo</au><au>Bertaccini, Alessandro</au><au>Manferrari, Fabio</au><au>Marcelli, Emanuela</au><au>Cochetti, Giovanni</au><au>Porreca, Angelo</au><au>Castellucci, Paolo</au><au>Fanti, Stefano</au><au>Brunocilla, Eugenio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2019-08</date><risdate>2019</risdate><volume>26</volume><issue>8</issue><spage>804</spage><epage>811</epage><pages>804-811</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>To evaluate the clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography on the planned management of prostate cancer patients with biochemical recurrence after surgery.
We enrolled 276 prostate cancer patients referred to
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography due to biochemical recurrence after surgery (two consecutive prostate-specific antigen assays ≥0.2 ng/mL). First, the detection rate of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed according to different prostate-specific antigen levels. Second, the independent predictors of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography positive results were assessed. Finally, the intended treatment before revision of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed by a multidisciplinary team based on the European Association of Urology guidelines, patient clinical condition and clinical parameters. Then, re-assessment of the treatment plan was prospectively recorded by the same board after revision of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography. The effective clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was rated as major (change in therapeutic approach), minor (same treatment, but modified therapeutic strategy) or none.
The overall detection rate of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 47.5%. Prostate-specific antigen at
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (odds ratio 3.52) and prostate-specific antigen doubling time <3 months (odds ratio 3.98) were independent predictors of positive
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography results (all P ≤ 0.03).
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography led to a major treatment change in 177 cases (64.1%), with a minor clinical impact of 2.5%. The overall clinical impact of
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 42.4%, 27.7%, 21.2% and 8.7% in men with prostate-specific antigen at
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography of 0.2-0.4, 0.5-1, 1.1-2 and >2 ng/mL, respectively.
Ga-prostate-specific membrane antigen positron emission tomography/computed tomography allows clinicians to radically change the intended treatment approach before imaging evaluation, in roughly two out three individuals.</abstract><cop>Australia</cop><pmid>31083784</pmid><doi>10.1111/iju.14012</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-8172 |
| ispartof | International journal of urology, 2019-08, Vol.26 (8), p.804-811 |
| issn | 0919-8172 1442-2042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2231994344 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Androgen Antagonists - therapeutic use Chemoradiotherapy, Adjuvant - methods Clinical Decision-Making - methods Feasibility Studies Humans Kallikreins - blood Male Membrane Glycoproteins - administration & dosage Middle Aged Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnosis Organometallic Compounds - administration & dosage Patient Selection Positron Emission Tomography Computed Tomography - methods Prospective Studies Prostate - diagnostic imaging Prostate - surgery Prostate-Specific Antigen - blood Prostatectomy Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - therapy Radiopharmaceuticals - administration & dosage |
| title | How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A29%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20does%2068%20Ga-prostate-specific%20membrane%20antigen%20positron%20emission%20tomography/computed%20tomography%20impact%20the%20management%20of%20patients%20with%20prostate%20cancer%20recurrence%20after%20surgery?&rft.jtitle=International%20journal%20of%20urology&rft.au=Bianchi,%20Lorenzo&rft.date=2019-08&rft.volume=26&rft.issue=8&rft.spage=804&rft.epage=811&rft.pages=804-811&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/iju.14012&rft_dat=%3Cproquest_cross%3E2231994344%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2231994344&rft_id=info:pmid/31083784&rfr_iscdi=true |